Baseline characteristics of 61 patients with sickle cell disease admitted to the ICU with acute parvovirus B19 infection
| . | NA . | Overall . | Erythroblastopenia . | BMN/CFE . | Other VO manifestations . | P value . |
|---|---|---|---|---|---|---|
| N = 61 . | n = 26 . | n = 17 . | n = 18 . | |||
| Age, y | 0 | 29 (24-38) | 28 (22-37) | 29 (27-40) | 26 (22-34) | .3 |
| Genotype, n (%) | 0 | <.001 | ||||
| SC | 19 (31.1) | 3 (11.5) | 11 (64.7) | 5 (27.8) | ||
| SS | 36 (59.0) | 22 (84.6) | 6 (35.3) | 8 (44.4) | ||
| Other | 6 (9.8) | 1 (3.8) | 0 (0) | 5 (27.8) | ||
| G6PD defect | 3 | 7 (12.1) | 5 (20.0) | 2 (13.3) | 0 (0) | .1 |
| Male gender | 0 | 29 (47.5) | 14 (53.8) | 6 (35.3) | 9 (50.0) | .5 |
| BMI, kg/m2 | 12 | 22.9 (20.7-25.6) | 21.6 (18.7-23.5) | 26.5 (23-30.8) | 22.6 (20.3-26.3) | .005 |
| Baseline hemoglobin, g/dL | 2 | 9 (8-11) | 8 (7-9) | 11 (9.5-12) | 10 (8-11) | <.001 |
| SCD history | ||||||
| ACS | 0 | 38 (62.3) | 20 (76.9) | 6 (35.3) | 12 (66.7) | .02 |
| VOC | 0 | 56 (91.8) | 24 (92.3) | 15 (88.2) | 17 (94.4) | .8 |
| Stroke or angiopathy | 0 | 2 (3.3) | 2 (7.7) | 0 (0) | 0 (0) | .2 |
| Retinopathy | 0 | 14 (23) | 6 (23.1) | 4 (23.5) | 4 (22.2) | >.99 |
| Priapism | 31 | 4 (13.3) | 0 (0) | 1 (16.7) | 3 (33.3) | .1 |
| Osteonecrosis | 1 | 8 (13.3) | 3 (11.5) | 4 (23.5) | 1 (5.9) | .3 |
| Cardiopathy | 0 | 5 (8.2) | 3 (11.5) | 0 (0) | 2 (11.1) | .3 |
| Allo-immunization | 0 | 8 (13.1) | 8 (30.8) | 0 (0) | 0 (0) | .002 |
| DHTR | 3 | 6 (10.3) | 6 (26.1) | 0 (0) | 0 (0) | .01 |
| Baseline creatinine, μM | 17 | 57 (45-73) | 62 (48-70) | 57 (44-78) | 54 (45-60) | .8 |
| Immunosuppression | 0 | 1 (1.6) | 0 (0) | 1 (5.9) | 0 (0) | .3 |
| Exsanguination program | 0 | 5 (8.2) | 2 (7.7) | 1 (5.9) | 2 (11.1) | .8 |
| Transfusion exchange program | 0 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| HU | 0 | 24 (39.3) | 16 (61.5) | 2 (11.8) | 6 (33.3) | .004 |
| B9 supplementation | 0 | 48 (78.7) | 22 (84.6) | 11 (64.7) | 15 (83.3) | .3 |
| . | NA . | Overall . | Erythroblastopenia . | BMN/CFE . | Other VO manifestations . | P value . |
|---|---|---|---|---|---|---|
| N = 61 . | n = 26 . | n = 17 . | n = 18 . | |||
| Age, y | 0 | 29 (24-38) | 28 (22-37) | 29 (27-40) | 26 (22-34) | .3 |
| Genotype, n (%) | 0 | <.001 | ||||
| SC | 19 (31.1) | 3 (11.5) | 11 (64.7) | 5 (27.8) | ||
| SS | 36 (59.0) | 22 (84.6) | 6 (35.3) | 8 (44.4) | ||
| Other | 6 (9.8) | 1 (3.8) | 0 (0) | 5 (27.8) | ||
| G6PD defect | 3 | 7 (12.1) | 5 (20.0) | 2 (13.3) | 0 (0) | .1 |
| Male gender | 0 | 29 (47.5) | 14 (53.8) | 6 (35.3) | 9 (50.0) | .5 |
| BMI, kg/m2 | 12 | 22.9 (20.7-25.6) | 21.6 (18.7-23.5) | 26.5 (23-30.8) | 22.6 (20.3-26.3) | .005 |
| Baseline hemoglobin, g/dL | 2 | 9 (8-11) | 8 (7-9) | 11 (9.5-12) | 10 (8-11) | <.001 |
| SCD history | ||||||
| ACS | 0 | 38 (62.3) | 20 (76.9) | 6 (35.3) | 12 (66.7) | .02 |
| VOC | 0 | 56 (91.8) | 24 (92.3) | 15 (88.2) | 17 (94.4) | .8 |
| Stroke or angiopathy | 0 | 2 (3.3) | 2 (7.7) | 0 (0) | 0 (0) | .2 |
| Retinopathy | 0 | 14 (23) | 6 (23.1) | 4 (23.5) | 4 (22.2) | >.99 |
| Priapism | 31 | 4 (13.3) | 0 (0) | 1 (16.7) | 3 (33.3) | .1 |
| Osteonecrosis | 1 | 8 (13.3) | 3 (11.5) | 4 (23.5) | 1 (5.9) | .3 |
| Cardiopathy | 0 | 5 (8.2) | 3 (11.5) | 0 (0) | 2 (11.1) | .3 |
| Allo-immunization | 0 | 8 (13.1) | 8 (30.8) | 0 (0) | 0 (0) | .002 |
| DHTR | 3 | 6 (10.3) | 6 (26.1) | 0 (0) | 0 (0) | .01 |
| Baseline creatinine, μM | 17 | 57 (45-73) | 62 (48-70) | 57 (44-78) | 54 (45-60) | .8 |
| Immunosuppression | 0 | 1 (1.6) | 0 (0) | 1 (5.9) | 0 (0) | .3 |
| Exsanguination program | 0 | 5 (8.2) | 2 (7.7) | 1 (5.9) | 2 (11.1) | .8 |
| Transfusion exchange program | 0 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| HU | 0 | 24 (39.3) | 16 (61.5) | 2 (11.8) | 6 (33.3) | .004 |
| B9 supplementation | 0 | 48 (78.7) | 22 (84.6) | 11 (64.7) | 15 (83.3) | .3 |
Bolded P values are significant to the P < .05 level.
BMI, body mass index; G6PD, glucose-6-phosphate dehydrogenase; NA, missing values; VOC, vaso-occlusive crisis.